- Home
- LYB vs RPRX Comparison
LYB vs RPRX Comparison
Compare LYB & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LYB | RPRX |
|---|---|---|
| Founded | 1955 | 1996 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.3B | 19.4B |
| IPO Year | 2010 | 2020 |
Fundamental Metrics
Financial Performance| Metric | LYB | RPRX |
|---|---|---|
| Price | $74.33 | $45.91 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 15 | 4 |
| Target Price | ★ $59.13 | $47.75 |
| AVG Volume (30 Days) | ★ 7.5M | 3.1M |
| Earning Date | 05-01-2026 | 05-06-2026 |
| Dividend Yield | ★ 4.10% | 2.01% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 1.78 |
| Revenue | ★ $30,153,000,000.00 | $2,378,193,000.00 |
| Revenue This Year | N/A | $38.30 |
| Revenue Next Year | $0.70 | $4.80 |
| P/E Ratio | ★ N/A | $26.22 |
| Revenue Growth | N/A | ★ 5.06 |
| 52 Week Low | $41.58 | $29.66 |
| 52 Week High | $75.62 | $47.86 |
Technical Indicators
Market Signals| Indicator | LYB | RPRX |
|---|---|---|
| Relative Strength Index (RSI) | 81.22 | 58.46 |
| Support Level | $43.01 | $35.32 |
| Resistance Level | N/A | $46.14 |
| Average True Range (ATR) | 3.01 | 0.90 |
| MACD | 1.09 | -0.19 |
| Stochastic Oscillator | 99.01 | 37.86 |
Price Performance
Historical ComparisonAbout LYB LyondellBasell Industries NV (Netherlands)
LyondellBasell is a petrochemical producer with operations in the United States, Europe, and Asia. The company is the world's largest producer of polypropylene and also a major producer of polyethylene and propylene oxide. Its chemicals are used in various consumer and industrial end products. Well over half of LyondellBasell's production comes from its North American operations.
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.